论文部分内容阅读
目的:观察丹红注射液联合瑞舒伐他汀治疗不稳定型心绞痛的临床疗效。方法:将84例不稳定型心绞痛患者随机分为实验组42例和对照组42例,对照组采用常规治疗,实验组在常规治疗的基础上加用丹红注射液及瑞舒伐他汀,疗程10 d,观察两组治疗前后心绞痛疗效及心电图的变化指标。结果:实验组总有效率分别为97.61%和71.42%,对照组分别为85.71%和54.76%,实验组均明显优于对照组(P<0.05)。结论:丹红注射液联合瑞舒伐他汀可有效减少不稳定型心绞痛患者心绞痛发作频率、降低不良事件的发生,有较好的推广价值。
Objective: To observe the clinical efficacy of Danhong injection combined with rosuvastatin in the treatment of unstable angina pectoris. Methods: Eighty-four patients with unstable angina were randomly divided into experimental group (n = 42) and control group (n = 42). The control group was treated by conventional therapy. The experimental group was given Danhong injection and rosuvastatin on the basis of routine treatment. 10 d, observed before and after treatment of angina pectoris and ECG changes in indicators. Results: The total effective rate in the experimental group was 97.61% and 71.42%, respectively, and that in the control group was 85.71% and 54.76%, respectively. The experimental group was significantly better than the control group (P <0.05). Conclusion: Danhong injection combined with rosuvastatin can effectively reduce the incidence of angina pectoris in patients with unstable angina pectoris and reduce the incidence of adverse events, which has a good promotion value.